Oncotarget

Research Papers:

Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21WAF1 pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells

Qiongshu Li _, Guomu Liu, Hongyan Yuan, Juan Wang, Yingying Guo, Tanxiu Chen, Ruiping Zhai, Dan Shao, Weihua Ni and Guixiang Tai

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:4253-4265. https://doi.org/10.18632/oncotarget.2973

Metrics: PDF 1106 views  |   HTML 1236 views  |   ?  


Abstract

Qiongshu Li1, Guomu Liu1, Hongyan Yuan1, Juan Wang1, Yingying Guo1, Tanxiu Chen1, Ruiping Zhai1, Dan Shao1, Weihua Ni1, Guixiang Tai1

1Department of Immunology, College of Basic Medical Science, Jilin University, Changchun 130021, China

Correspondence to:

Guixiang Tai, e-mail: taiguixiang@163.com

Keywords: MUC1, pSmad3L, pSmad3C, HCC, JNK

Received: November 14, 2014     Accepted: December 16, 2014     Published: January 20, 2015

ABSTRACT

Mucin1 (MUC1) is a transmembrane glycoprotein that acts as an oncogene in human hepatic tumorigenesis. Hepatocellular carcinoma (HCC) cells often gain advantage by reducing the tumor-suppressive activity of transforming growth factor beta (TGF-β) together with stimulation of its oncogenic activity as in MUC1 expressing HCC cells; however, molecular mechanisms remain largely unknown. Type I TGF-β receptor (TβRI) and c-Jun NH2-terminal kinase (JNK) differentially phosphorylate Smad3 mediator to create 2 phosphorylated forms: COOH-terminally phosphorylated Smad3 (pSmad3C) and linker-phosphorylated Smad3 (pSmad3L). Here, we report that MUC1 overexpression in HCC cell lines suppresses TβRI-mediated pSmad3C signaling which involves growth inhibition by up-regulating p21WAF1. Instead, MUC1 directly activates JNK to stimulate oncogenic pSmad3L signaling, which fosters cell proliferation by up-regulating c-Myc. Conversely, MUC1 gene silencing in MUC1 expressing HCC cells results in preserved tumor-suppressive function via pSmad3C, while eliminating pSmad3L-mediated oncogenic activity both in vitro and in vivo. In addition, high correlation between MUC1 and pSmad3L/c-Myc but not pSmad3C/p21WAF1 expression was observed in HCC tissues from patients. Collectively, these results indicate that MUC1 shifts Smad3 signaling from a tumor-suppressive pSmad3C/p21WAF1 to an oncogenic pSmad3L/c-Myc pathway by directly activating JNK in HCC cells, suggesting that MUC1 is an important target for HCC therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2973